HPV Env Specific Neutra™ Antibody Products

Are you struggling to overcome challenges in HPV therapeutic development, such as inefficient viral neutralization assays or inconsistent antibody specificity? Creative Biolabs' HPV Env specific Neutra™ antibody products leverage advanced recombinant antibody engineering and rigorously validated functional assays to deliver high-affinity antibodies, enabling precise targeting of HPV envelope glycoproteins and accelerating the development of vaccines and therapeutics.

Introduction to HPV Env

Human papillomavirus envelope glycoprotein (HPV Env) is a critical structural component of the virion, essential for host cell entry and infection. As a major antigenic target, HPV Env mediates viral attachment to host receptors and membrane fusion, making it pivotal for both pathogenesis and immune evasion.

Fig.1 Role of HPV Env in the early stages of HPV infection.¹

• Basic Information

HPV Env is a highly conserved surface protein expressed during the late stages of viral replication. It is classified into two subunits: L1, the primary capsid protein forming the virus shell, and L2, a minor protein facilitating genome packaging and infection. These proteins self-assemble into virus-like particles (VLPs), which underpin prophylactic vaccine design.

• Structural Insights

The L1 protein forms pentameric capsomeres that assemble into an icosahedral lattice, while L2 binds to the viral genome and directs intracellular trafficking. Cryo-EM studies reveal conformational flexibility in HPV Env's receptor-binding domains, enabling immune evasion. Neutralizing epitopes are concentrated on surface-exposed loops of L1, which antibodies target to block receptor interaction.

• Related Signaling Pathways

HPV Env activates host integrin-mediated signaling pathways to facilitate viral entry, triggering cytoskeletal rearrangements and endocytosis. It also modulates NF-κB and interferon pathways to suppress innate immune responses, prolonging infection and enabling persistent lesions.

• Associated Diseases

HPV infection is linked to cervical, oropharyngeal, and anogenital cancers, accounting for 5% of global cancer burden. Persistent high-risk HPV strains (e.g., HPV16, HPV18) drive oncogenesis through E6/E7 oncoproteins, but Env-specific antibodies play a critical role in preventing initial infection and reducing transmission.

Applications of HPV Env Neutralizing Antibodies

• Vaccine Efficacy Evaluation

HPV Env antibodies are indispensable for validating vaccine-induced immunity. By quantifying neutralizing titers via PBNA, researchers correlate antibody levels with clinical protection, ensuring compliance with WHO guidelines for HPV vaccine standardization.

• Antiviral Therapeutic Development

Monoclonal antibodies targeting HPV Env show promise in blocking viral entry and clearing persistent infections. Preclinical studies demonstrate their ability to prevent cervicovaginal HPV transmission in animal models, offering a non-surgical alternative for high-risk patients.

• Diagnostic and Epidemiological Monitoring

Serum neutralization assays using HPV Env antibodies provide accurate seroprevalence data, identifying populations with subprotective immunity and guiding booster vaccination strategies. These tools are critical for public health initiatives in HPV-endemic regions.

• Oncology Research

By inhibiting HPV entry, neutralizing antibodies reduce the risk of viral integration into host DNA—a key step in oncogenesis. This supports research into preventive strategies for HPV-associated cancers.

Our Anti-HPV Env Antibodies

Creative Biolabs' HPV Env-neutralizing antibodies are engineered for high specificity against conformational epitopes on L1, effectively disrupting viral attachment and entry. Validated in pseudovirus neutralization assays (PBNA), these antibodies enable:

- Quantitative Assessment of Vaccine Efficacy: Measure neutralizing antibody titers in vaccinated individuals to confirm immune protection.

- Therapeutic Candidate Screening: Identify antibodies with cross-strain neutralization potential for broad-spectrum therapies.

- Diagnostic Development: Detect HPV-specific immune responses in patient sera with high sensitivity.

Creative Biolabs provides HPV Env specific Neutra™ antibody products, engineered to enhance your research development with precision, reliability, and scalability. Our antibodies are validated across pseudovirus neutralization, ELISA, and flow cytometry platforms, ensuring seamless integration into your workflow.

Contact our scientific team today to discuss your project requirements or request a product dossier.

REFERENCE

1. Carse, Sinead, Martina Bergant, and Georgia Schäfer. "Advances in targeting hpv infection as potential alternative prophylactic means." International journal of molecular sciences 22.4 (2021): 2201. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms22042201